Oxurion NV is a company specializing in acquiring majority stakes in promising European pharmaceutical subcontractors. Oxurion NV's ambition is to build an integrated group of subcontractors serving healthcare players. Oxurion NV holds a 72% stake in Axiodis CRO, a subcontractor specialized in biometrics.

Employees

Sector

Biotechnology & Medical Research

Calendar

04-02 Earnings release - Annual 2026

More about the company

Quotes

Date	Price	Change	Volume
16/10/26	€0.000800	0.00%	115,001
15/10/26	€0.000800	0.00%	260,234
14/10/26	€0.000800	-20.00%	303,996
13/10/26	€0.001000	0.00%	183,000
12/10/26	€0.001000	-16.67%	735,950

Real-time Euronext Bruxelles

More quotes

Market Closed - Euronext Bruxelles 19:55:00 16/10/2026 +04			5-day change	1st Jan Change
0.000800 ^EUR	0.00%		-33.33%	-88.89%

07-21	Oxurion's Axiodis Partners with KYomed on Clinical Biometrics Services	MT
06-02	Oxurion Positions Itself in the GLP-1 Therapy Market

Market Cap	113K 127K 104K 94.94K 179K 12.02M 182K 1.25M 492K 6.27M 475K 465K 20M	P/E 2024	2.56x	P/E 2025	-0.05x
Enterprise Value	11.12M 12.52M 10.31M 9.38M 17.7M 1.19B 17.99M 124M 48.59M 620M 46.97M 45.97M 1.98B	EV / Sales 2024	3,879x	EV / Sales 2025	20.7x
Free-Float	83.71%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Bruxelles	OXUR	Real-time
CBOE	THR	Real-time
Deutsche Boerse AG	TG40	End-of-day quote
CBOE	0G99	Real-time
Börse Stuttgart	TG40	Delayed
Boerse Muenchen	TG40	Real-time

07-21	Oxurion's Axiodis Partners with KYomed on Clinical Biometrics Services	MT
06-02	Oxurion Positions Itself in the GLP-1 Therapy Market
06-02	Oxurion Ends Talks to Buy Majority Stake in France-based CRO	MT
04-30	Oxurion NV Auditor Raises 'Going Concern' Doubt	CI
04-30	Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-19	Oxurion NV signs a letter of intent for acquisition of an International CRO	RE
03-02	Oxurion Extends Talks for Acquisition of Majority Stake in French CRO	MT
01-19	Oxurion Temporarily Suspends Digital Assets Investment Project Amid Crypto Volatility	MT
14/10/25	Oxurion to Acquire Majority Stake in French Contract Research Organization	MT
01/10/25	Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2025	CI
05/08/25	Oxurion Receives Improved EUR30 Million Indicative Financing Offer from Atlas Special	MT
22/07/25	Oxurion Plans EUR10 Million Bond Issue to Fund Treasury Diversification	MT
22/07/25	Oxurion NV announced that it expects to receive ?10 million in funding from Atlas Special Opportunities LLC	CI

Oxurion NV Stock

Stocks

OXUR

BE0974487192

Biotechnology & Medical Research

Valuation: Oxurion NV

Chart: Oxurion NV

Latest news: Oxurion NV

Press Releases: Oxurion NV

News in other languages: Oxurion NV

Quotes and Performance

Price Extremes

Managers and Directors: Oxurion NV

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

10-15	Oxurion Nv : Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC	AT
10-12	Oxurion Nv : Oxurion Receives Transparency Notifications from Market Wizards B.V. and Atlas Special Opportunities II LLC	AT
10-09	Oxurion Nv : Oxurion Receives Transparency Notification from Market Wizards B.V.	AT
09-30	Oxurion : Interim Financial Report — Half-year results as of 30 June 2026 (EN)	PU
09-30	Oxurion Nv : Oxurion Publishes First Half 2026 Results	AT

10-15	Oxurion Nv : Oxurion ontvangt transparantiekennisgevingen van Market Wizards B.V. en van Atlas Special Opportunities II LLC
10-12	Oxurion Nv : Oxurion ontvangt transparantiekennisgevingen van Market Wizards B.V. en van Atlas Special Opportunities II LLC
10-09	Oxurion Nv : Oxurion ontvangt transparantiekennisgeving van Market Wizards B.V.
10-08	Oxurion Nv : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
09-30	Oxurion : Tussentijdse halfjaarresultaten 30 juni 2026 (NL)

1 week	-33.33%
Current month	-42.86%
1 month	-71.43%
3 months	-71.43%
6 months	-80.00%
Current year	-88.89%

Manager	Title	Age	Since
Ghoson Pascal CEO	Chief Executive Officer	37	28/12/2023
Philippe Barbeaux CTO	Chief Tech/Sci/R&D Officer	-	28/12/2023
Samuel Darcheville SEC	Corporate Secretary	-	28/12/2023

Director	Title	Age	Since
Ghoson Pascal BRD	Director/Board Member	37	28/12/2023
James Hartmann BRD	Director/Board Member	60	28/12/2023
Charles Paris de Bollardire CHM	Chairman	-	28/12/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/03/22	Ecp Liquid Fund 1 LLC	Buy	Company	1,180	0.0030%
11/03/22	Midelco NV	Buy	Company	1,180	0.0030%
17/11/21	Thomas Clay	Buy	Chairman	2,766	0.0072%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OXURION NV	0.00%	-33.33%	-94.81%	-99.99%	127K
WUXI APPTEC CO., LTD.	-6.60%	-8.56%	+49.38%	+63.51%	65B
LONZA GROUP AG	+0.03%	+5.56%	+9.10%	+69.05%	51.2B
ARGENX SE	-4.09%	-0.11%	+2.22%	+53.15%	51.19B
IQVIA HOLDINGS INC.	-1.53%	+2.70%	+30.48%	+34.12%	43.93B
BEONE MEDICINES AG	-1.34%	+4.12%	+16.64%	+115.13%	41.96B
REVOLUTION MEDICINES, INC.	-5.97%	-6.22%	+228.95%	+454.22%	38.14B
CELLTRION, INC.	+6.53%	+8.02%	+16.40%	+53.41%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.49%	+37.09%	-3.70%	25.2B
GENMAB A/S	-1.07%	+2.33%	+19.43%	+9.98%	22.5B
Average	-1.49%	-3.68%	+31.49%	+74.89%	37.24B
Weighted average by Cap.	-2.20%	-0.54%	+44.25%	+96.53%

	2024	2025
Net sales	3K 3.37K 2.78K 2.53K 4.77K 320K 4.85K 33.42K 13.1K 167K 12.67K 12.4K 533K	555K 624K 514K 468K 883K 59.26M 897K 6.18M 2.42M 30.92M 2.34M 2.29M 98.58M
Net income	119K 134K 110K 100K 189K 12.71M 192K 1.33M 520K 6.63M 502K 492K 21.14M	-3.73M -4.19M -3.46M -3.14M -5.93M -398M -6.03M -41.53M -16.28M -208M -15.74M -15.4M -662M
Net Debt	10.87M 12.23M 10.08M 9.17M 17.3M 1.16B 17.58M 121M 47.49M 606M 45.9M 44.93M 1.93B	11.01M 12.39M 10.21M 9.29M 17.52M 1.18B 17.8M 123M 48.1M 614M 46.49M 45.5M 1.96B

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.02
3 years	0		18
5 years	0		23,700
10 years	0		104,600